Clinical Trial

A Study of Telitacicept in Lupus Nephritis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-12-26; most recent amendment 2024-09-19.
Status change: Not Yet Recruiting → Recruiting 2023-10-10
Trial Details
NCT Number NCT05680480
Lead Sponsor RemeGen Co., Ltd.
Conditions Lupus Nephritis
Enrollment 120 participants
Start Date 2023-04-17
Primary Completion 2025-12 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-23